It's been another tough week for ASX healthcare but Morgans' Scott Power said there's been bright spots with Racura soaring on trial news.

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of ...

SYDNEY, March 17, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

Operator: Thank you for standing by, and welcome to Kyntra Bio, Inc.’s fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode.

HIGHLIGHTS Oral presentation on key results from the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European ...

In patients who had progressed on one prior ARPI, FG3246 plus enzalutamide yielded a median radiographic progression-free survival (rPFS) of 10.1 months and PSA50 response of 40%. Phase I Monotherapy ...

Let's see what is getting investors excited today. The post Why is this ASX 300 stock rocketing 17% today? appeared first on The Motley Fool Australia.

When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...